卵巢癌精准医学检测:商业保险与医疗补助患者间的不平等加剧
基于美国IBM Truven Health MarketScan数据库,纳入2011至2017年接受卵巢癌手术的27181例患者,其中商业保险占88.6%、医疗补助占11.4%。两组精准医学检测率均随时间上升,但商业保险与医疗补助患者间的检测率差异从5.6%扩大至9.0%(p<0.0001),主要驱动于胚系和体细胞基因检测差异从7.6%扩大至21.3%(p<0.0001)。
要点
- 商业保险与医疗补助卵巢癌患者的精准医学检测率差距随时间扩大。
- 检测率不平等加剧主要由胚系和体细胞基因检测差异驱动。
- 社会经济弱势患者精准医学检测可及性改善相对滞后。
核心结论
- 商业保险与医疗补助卵巢癌患者间精准医学检测率的不平等随时间加剧。
研究设计与样本
- 回顾性队列研究,使用IBM Truven Health MarketScan研究数据库,纳入2011至2017年美国卵巢癌手术患者27181例。
主要发现
- 商业保险患者占88.6%,医疗补助患者占11.4%。
- 商业保险患者检测率从47.0%升至66.6%,医疗补助患者从41.4%升至57.6%(p<0.0001)。
- 两组检测率差异从5.6%扩大至9.0%(p<0.0001)。
- 胚系和体细胞基因检测差异从7.6%扩大至21.3%(p<0.0001)。
临床怎么用
- 临床应关注医疗补助卵巢癌患者的精准医学检测可及性,减少检测不平等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Precision medicine technologies have significant impact in the care of patients with ovarian cancer. Compared to affluent patients, socioeconomically vulnerable patients are less likely to have access to this testing. There is little data that demonstrate this inequity over time. METHODS: We used the IBM Truven Health MarketScan Research Database to identify patients in the United States who underwent surgery for ovarian cancer between 2011 and 2017. The presence of claims for precision medicine testing within six months of surgery was assessed for each patient. Precision medicine testing included both molecular genetic testing (BRCA limited or full sequencing, somatic and germline testing) as well as ancillary pathology tests (immunohistochemistry, microsatellite instability). Demographic data was extracted. RESULTS: We identified 27,181 patients who met eligibility. Of these, 88.6% had commercial insurance, and 11.4% had Medicaid. While the proportion of patients who underwent precision medicine testing increased over time for both cohorts (47.0% to 66.6% for commercially insured, 41.4% to 57.6% for Medicaid insured, p < 0.0001), the inequity in testing rates widened (5.6% disparity to 9.0%, p < 0.0001). This was driven by growing inequity in germline and somatic genetic testing (7.6% disparity to 21.3%, p < 0.0001). CONCLUSIONS: There is widening inequity in precision medicine testing rates between commercially insured and Medicaid insured poate patients with ovarian cancer.
引用
- Gamble CR, Huang Y, Wright JD, et al. Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance. Gynecol Oncol. 2021. PMID: 33958212. doi:10.1016/j.ygyno.2021.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。